disease target News
-
Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar
Date: Thursday, February 3, 2022 Time: 2pm ET / 11am PT Duration: 1 Hour Sign up here to go to the webinar Improving the discovery of novel drugs with artificial intelligence Last year, Toronto-based Deep Genomics used artificial intelligence to scan 200,000 genomes from people with a variety of diseases, and in so doing identified a disease target—Wilson’s—as well ...
-
Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases
Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale; and Calico Life Sciences, a biotechnology organization focused on age-related interventions and founded by Alphabet and Arthur D. Levinson, today announced a research collaboration to discover and develop small molecule ...
-
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’s portfolio. Novel chronic kidney disease (CKD) target from the partnership enters AstraZeneca’s portfolio AI-generated ...
By Benevolent
-
Defymed at the conference of the European Society for Biomaterials
September 5th-9th: Defymed at the conference of the European Society for Biomaterials Last year Defymed attended for the first time to the World Biomaterials Congress which held on December 11-15, 2020 via an excellent virtual platform. This year Defymed confirms its strong interest on biomaterials, improvement performed to process them and how they could be used in conjunction with other ...
By Defymed
-
ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales The collaboration further validates ...
-
Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery ...
By Suono Bio
-
Symic Bio Selected for “The Best of The Liver Meeting 2018” at AASLD
SAN FRANCISCO, November 9, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for “The Best of The Liver Meeting 2018” at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco. Symic's molecule, SBR-294, is ...
-
MoreNova Turbo: a Flexible Shockwaves Unit
MoreNova Turbo (MT) is a shockwaves device incorporating a compact and powerful energizer, in-line ultrasound localizer and easily interchangeable high-efficiency applicators. The novel applicators are designed to respectively deliver point, linear or planar shockwaves compatible with treating urinary stones, calcified leg arteries, prostate, Chronic Kidney Disease (CKD) and more. Target ...
By DirexGroup
-
AptaMatrix, Inc. Receives a NIH Small Business Innovation Research Phase II Award
AptaMatrix, Inc., a Syracuse-based biotech company focused on developing aptamer-based technologies for diagnostic applications, announces that it has been awarded a $2M Phase II Small Business Innovation Research (SBIR) grant by the National Institute of General Medical Sciences (NIGMS) institute of the National Institutes of Health (NIH). The Phase II award will allow AptaMatrix to develop and ...
-
D-Kimia expands to further support North American Market
D-Kimia Diagnostic Solutions announces the opening of its offices in New York to support its growing partnerships with US diagnostic labs and further develop its companion testing solutions with major anti-viral treatments. Hepatitis C (HCV) affects an estimated 5 million Americans and there is a growing concern of a much larger undiagnosed population. The CDC now recommends all baby boomers ...
By D-Kimia, LLC
-
BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca’s Portfolio
Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021 London, 15 December 2021: BenevolentAI, a leading ...
By Benevolent
-
Vybion New Drug Webinar for Huntington`s Patients
Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. The company believes that Intrabodies can achieve both the specificity and safety of ...
By Vybion
-
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
Researchers describe rapid, low-cost drug development approach Paper also reports preclinical and early clinical data for LMN-101 A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience report in Nature ...
-
Agilent Technologies Introduces OneSeq to Streamline Cytogenetic Research
Agilent Technologies Inc. (NYSE: A) today introduced OneSeq, the industry's first all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research. Agilent is showcasing the new product at the annual Advances in Genome Biology ...
-
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
-
Creative Biostructure Offers MagHelix™ FBDD Platform for Lead Discovery and Optimization
As an expert in the field of structural biology, Creative Biostructure offers MagHelix™ FBDD Platform, an integrated platform covering the entire FBDD process, equipped with advanced biophysical detection instruments, providing customized drug discovery solutions for a wide range of disease areas and therapeutic targets. Fragment-based drug discovery (FBDD) is a powerful approach to ...
-
Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has treated the first patient in trial AKST4290-206 (STEEL) studying the effect of AKST4290 on choroidal blood flow (ChBF) in ...
-
Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year is free to attend. ...
-
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded by Leading Biopharma VCs and the Israeli Innovation Authority
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech ...
-
SFA Therapeutics, Inc. announces start of phase 1B clinical trial in the treatment of mild-to-moderate plaque psoriasis
SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start of our first clinical trial for the treatment of “the appearance of the structure of skin with plaques due to psoriasis.” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you